Overview

To Evaluate the Efficacy and Safety of Co-administrated Ezetimibe/Rosuvastatin and Telmisartan in Patients With Essential Hypertension and Primary Hypercholesterolemia

Status:
Recruiting

Trial end date:
2022-05-19

Target enrollment:

Participant gender:

Summary

This study is a multicenter, Randomized, double-blind, acitve-controlled, Phase 3 Clinical Trial in 8 weeks for screening, twice Investigational product administer, Follow up visit.

Phase:

Phase 3

Details

Lead Sponsor:

Hanlim Pharm. Co., Ltd.

Treatments:

Ezetimibe
Rosuvastatin Calcium
Telmisartan